Home
About
- Our Team
- Careers
News
Contact

Technology
Diagnostics
Therapeutics
- Drug Discovery
- Safer Drugs
Products
- Sales
- Licensing & Distribution
Services
Resources

AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

February 2012/in News, PIONEERING NEW TECHNOLOGIES /by Kenneth Rothschild

Share this entry

http://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild http://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2012-02-27 13:46:482016-11-10 12:44:59AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

Menu

Home
About
Technology
Diagnostics
Therapeutics

Products
Services
Resources
News
Contact

Get in Touch

AmberGen, Inc.

313 Pleasant St.

Watertown, MA 02472

(617) 932-9990

info@ambergen.com

Recent News

Recent Posts

Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry. January 2017
AmberGen awarded two US Patents (9,334,530 and 9,523,680) providing broad coverage for its Bead-AMS™ technology December 2016

© 2017 - AmberGen Inc. Website designed in Massachusetts

Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent... AmberGen awarded Phase I SBIR grant for development of a multiplex in vitro...

Scroll to top